Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,281 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: HIV Infections
Interventions: HIV screening strategies; Other
Lead sponsor: Westat; Other
Eligibility: 14 Years to 24 Years
Enrollment: 84,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: Prevention of HIV Infection, HIV Antibodies, Monoclonal Antibody, Human, Neutralizing Antibody
Interventions: VRC-HIVMAB080-00-AB (VRC01LS), VRC-HIVMAB060-00-AB (VRC01); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infection
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 90 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV/AIDS
Interventions: Risk reduction behavioral intervention, Wellness Promotion Intervention; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Coronavirus Infections, Healthcare Associated Infection
Interventions: Inhaled nitric oxide gas; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV/AIDS, Stimulant Use Disorders
Interventions: Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS), Contingency Management (CM); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions: Oral Vancomycin, Placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: HIV Infections, Hiv, Sexually Transmitted Infections (Not HIV or Hepatitis), Sexually Transmitted Diseases, Sexual Behavior, Risk Reduction
Interventions: Para ti, para mi, para nosotros (P3), Waitlist Control Para ti, para mi, para nosotros (P3); Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acquired Immunodeficiency Syndrome
Interventions: Couples HIV counseling and testing, Women's relationship-focused HIV counseling and testing; Behavioral
Lead sponsor: National Development and Research Institutes, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Neurodevelopmental Outcomes
Interventions: Survey; Other
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years to 10 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Interventions: Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Atlanta, Georgia • Louisville, Kentucky • Ann Arbor, Michigan + 8 more

Conditions: Meningococcal Infections
Interventions: MenACWY-CRM, Licensed meningococcal ACWY vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 2,907 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 52
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 39 more

Conditions: Antimicrobial Prophylaxis
Interventions: daptomycin 6 mg/kg IV; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Participants
Interventions: Fluzone® High-Dose (HD) influenza vaccine, MK-1406 Injection, Placebo; Biological · Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 49 Years
Enrollment: 710 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Pregnancy (Unwanted), Sexually Transmitted Disease (STD), HIV Infection, Sexual Behavior
Interventions: #TranscendentHealth, Universal Sexual Health Program; Behavioral
Lead sponsor: Center for Innovative Public Health Research; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 467 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Clemente, California

Conditions: Healthy
Interventions: INO-3605, INO-3609, INO-3401, INO-3605 AND INO-3609, INO-3510, Seasonal Influenza vaccine; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Miami, Florida • Overland Park, Kansas • Baltimore, Maryland

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Nystatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Birmingham, Alabama • Princeton, New Jersey

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Youthnet Internet-based program, Control Internet based program; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 25 Years
Enrollment: 2,622 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID -19, COVID-19 (Prevention)
Interventions: MDX2301, Normal Saline; Biological
Lead sponsor: ModeX Therapeutics, An OPKO Health Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Pathogen Transmission, Patient Participation, Aging
Interventions: Clean Hands Accessible and Manageable for Patients; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 65 Years and older
Enrollment: 293 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: HIV Infection
Interventions: Linkage-to-Care Component: Financial Incentive (FI), Linkage-to-Care Component: Standard of Care (SOC), Viral Suppression Component: FI, Viral Suppression Component: SOC, Prevention for Positives Component: Counseling and SOC, Prevention for Positives Component: SOC; Behavioral
Lead sponsor: HIV Prevention Trials Network; Network
Eligibility: Not listed
Enrollment: 18,442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Influenza
Interventions: Trivalent Influenza Virus Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 3
States / cities: Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: Kidney Transplant, Urinary Tract Infection(UTI), Antibiotic Prophylaxis, Remote Patient Monitoring, Feasibility Pilot Study
Interventions: Trimethoprim-Sulfamethoxazole (TMP-SMX), Usual Care; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Years to 29 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2033
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery
Interventions: Azithromycin Injection, Placebo, Standard of Care Preoperative antibiotics; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more

Search by objective public record fields.

Screen2Prevent (S2P)

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

Antibiotic Prophylaxis Before Percutaneous Gastrostomy

A Couple-based HIV Prevention Intervention to Promote HIV Protection Among Latino Male Couples

NO Prevention of COVID-19 for Healthcare Providers

RCT of an Integrative Intervention for Non-Treatment-Seeking Meth Users

Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

Acceptability, Feasibility, and Preliminary Impact of a Web-based, HIV Prevention Toolkit With Cisgender Male Couples in Lima, Peru

HIV Prevention Intervention for Couples

Neurodevelopmental Outcomes and Fluconazole Prophylaxis

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

A Pilot Study of Daptomycin for Antimicrobial Prophylaxis

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)

#TranscendentHealth: A Text Messaging Pregnancy Prevention Program for Transgender Boys

A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

Effectiveness of an Online Prevention Program in Reducing the Risk of STD Infection in Young Adults

A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

Clean Hands Accessible and Manageable for Patients (CHAMPs)

Evaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention Strategies

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Antibiotics for Kidney Transplant Recipients

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial